All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DIOS-202,DIOS-203
Therapeutic Area: Infections and Infectious Diseases Product Name: DIOS-202
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CV7301
Therapeutic Area: Infections and Infectious Diseases Product Name: CV7301
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $1,100.0 million Upfront Cash: $147.1 million
Deal Type: Collaboration July 20, 2020
Details:
Under the terms of the agreement, GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration and CureVac will be responsible for the preclinical- and clinical development through Phase 1 trials of these projects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Povidone-Iodine
Therapeutic Area: Infections and Infectious Diseases Product Name: Betadine
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Testing has demonstrated BETADINE's® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, Skin Cleanser, Gargle and Mouthwash and Throat Spray.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IgY antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the infection process. IgNova's technology offers a safe, economical, and unlimited source of polyclonal antibodies to control SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a major criterion supporting that the vaccine candidate has the potential to induce a strong immunologic response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: $180.0 million Upfront Cash: $135.0 million
Deal Type: Collaboration March 16, 2020
Details:
The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
Details:
BioNTech intends to initiate clinical testing for BNT162 in late April 2020, as part of a global clinical development program in Germany, the United States and China for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): nCoV-2019 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $34.0 million Upfront Cash: $8.3 million
Deal Type: Collaboration January 31, 2020
Details:
The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible for Protection against Corona virus.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
